Biogen Idec Inc (BIIB)

BIIB (NASDAQ:Drugs)
$321.00
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | BIIB Avg Daily Volume: 1,259,000
Last Update: 10/30/14 - 3:59 PM EDT
Volume: 0
YTD Performance: 14.82%
Open: $0.00
Previous Close: $321.00
52 Week Range: $230.25 - $358.89
Oustanding Shares: 236,155,407
Market Cap: 74,403,122,529
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 11 10
Moderate Buy 1 1 1 1
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.65 1.65 1.65 1.69
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 29.84
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
29.84 29.80 26.77
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-6.83% 28.94% 170.38%
GROWTH 12 Mo 3 Yr CAGR
Revenue 32.60 0.47 0.14
Net Income 34.90 1.07 0.27
EPS 35.70 0.97 0.25
Earnings for BIIB:
EBITDA 1.90B
Revenue 5.81B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $3.69 $n.a. $13.42 $16.77
Number of Analysts 1 0 1 1
High Estimate $3.69 $n.a. $13.42 $16.77
Low Estimate $3.69 $n.a. $13.42 $16.77
Prior Year $2.33 $2.45 $8.93 $13.42
Growth Rate (Year over Year) 58.37% n.a.% 50.28% 24.96%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Still, it's a good time to review what's happening, so we never forget.
Some growth leaders in the sector are getting technical support.
Bearish
Oct 23, 2014 | 6:43 AM EDT
Shares of BIIB now seen reaching $407, according to Nomura. Estimates also reduced, as Avonex is facing increased competition. Buy rati...
Use one short and one buy.
Update
Sep 08, 2014 | 7:12 AM EDT
Morgan Stanley Healthcare Conference

Bionic or Just Plain? Real Money Pro($)

Checking two biotech charts.
Biotech stocks are thriving in a slower-growth, low-inflation world.

Recommended Viewing Real Money Pro($)

Take the ice bucket challenge?

Off the Charts Real Money Pro($)

As the action continues to the downside, we have no long positions on the table.

Off the Charts Real Money Pro($)

For the first time in months, we have no long positions on the table.

Columnist Conversations

Lang:
On this Halloween day we reflect on a month of wide swings and volatility. Just two weeks ago it appeared the...
Lang:
An amazing 80 trillion yen of stimulus announced by Japan overnight has an overwhelming impact on futures. As ...
Happy Halloween! The shops are full of spooky stuff but if you still can't decide what to wear tonight, here's...
Good day in market with DJIA leading the gains, albeit with a big assist from Visa (V) which soared on earning...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.